L-methylfolate plus SSRI or SNRI from treatment initiation compared to SSRI or SNRI monotherapy in a major depressive episode

Innovations in Clinical Neuroscience

Volumn 8, Issue 1, 2011, Pages 19-28

  Ginsberg, Lawrence D ^a   Oubre, Alondra Y ^b   Daoud, Yahya A ^c  

^a Red Oak Psychiatry Associates   (United States)

^b Writing Assistance   (United States)

^c BAYLOR HEALTH CARE SYSTEM   (United States)

Author keywords

Folate; L methylfolate; Major depressive disorder; SNRI; SSRI; Treatment initiation

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; FOLIC ACID DERIVATIVE; LEVO METHYLFOLATE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; AGITATION; ARTICLE; BODY WEIGHT; CLINICAL GLOBAL IMPRESSION SCALE; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIABETES MELLITUS; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FUNCTIONAL STATUS; HOSPITALIZATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENOPAUSE; MONOTHERAPY; NAUSEA; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN; XEROSTOMIA;

EID: 79959307811     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Hyman S, Chisholm D, Kessler R, et al.Mental disorders. In: Jamison DT, Breman JG, Measham AR, et al.Disease Control Priorities in Developing Countries, Second Edition. New York: Oxford University Press; 2006:591-605.
2. Keller MB. The long-term treatment of depression. J Clin Psychiatry. 1999;60(Suppl 17):41-45.
3. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: A literature review and a proposal for a novel approach to improve practice. Psychother Psychosom. 2006;75(3):139-153.
4. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157(4 Suppl):1-45.
5. Rush JA, Trivedi MH, Wisniewski SR, et al.Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
6. Trivedi MH, Rush AJ, Wisniewski SR, et al.Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
7. Paykel ES, Ramana R, Cooper Z, et al.Residual symptoms after partial remission: An important outcome in depression. Psychol Med. 1995;25(6):1171-1180.
8. Stahl S. Combining antidepressant therapies from the initiation of treatment: A paradigm shift for major depression. J Clin Psychiatry. 2009;70(11):1493-1494.
9. Nelson CJ, Mazure CM, Jatlow PI, et al.Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized study. Biol Psychiatry. 2004;55(3):296-300.
10. Blier P, Ward HE, Tremblay P, et al.Combination of antidepressant medications from treatment initiation for major depressive disorder: A double-blind randomized study. Am J Psychiatry. 2010;167(3):281-288.
11. Blier P, Gobbi G, Turcotte JE, et al.Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 2009;19(7):457-465.
12. Godfrey PS, Toone BK, Carney MW, et al.Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336(8712):392-395.
13. Ebert D, Jaspert A, Murata H, Kaschka WP. Initial lithium augmentation improves the antidepressant effects of standard TCA treatment in non-resistant depressed patients. Psychopharmacology (Berl). 1995;118(2):223-225.
14. Fava M, McCall WV, Krystal A, et al.Exzopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59(11):1052-1060.
15. Di Palma C, Urani R, Argicola R, et al.Is methylfolate effective in relieving major depression in chronic alcoholics? a hypothesis of treatment. Curr Ther Res. 1994;55(5):559-568.
16. Guaraldi GP, Fava M, Mazzi F, et al.An open trial of methyltetrahydrofolate in elderly depressed patients. Ann Clin Psychiatry. 1993;5(2):101-105.
17. Passeri M, Cucinotta D, Abate G, et al.Oral 5-methyltetrahydofolic acid in senile organic mental disorders with depression: Results of a doubleblind multicenter study. Aging Clin Exp Res. 1993;5(1):63-71.
18. Stahl SM. Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. CNS Spectr. 2007;12(10):739-44.
19. Wesson VA, Levirr AJ, Joffe RT. Change in folate status with antidepressant treatment. Psychiatry Res. 1994;53(3):313-322.
20. Abou-Saleh MT, Coppen A. Serum and red blood cell folate in depression. Acta Psychiatr Scand. 1989;80(1):78-82.
21. Alpert M, Silva RR, Pouget ER. Prediction of treatment response in geriatric depression from baseline folate level: Interaction with an SSRI or a tricyclic antidepressant. J Clin Psychopharmacol. 2003;23(3):309-313.
22. Papakostas GI, Losifescu DV, Renshaw PF, et al.Brain MRI white matter hyperintensities and onecarbon cycle metabolism in non geriatric outpatients with major depressive disorder (Part II). Psychiatry Res. 2005;140(3):301-307.
23. Alpert JE, Fava M. Nutrition and depression: The role of folate. Nutr Rev. 1997;55(5):145-149.
24. Levitt AJ, Joffe RT. Folate, B12, and life course of depressive illness. Biol Psychiatry. 1989;25(7):867-872.
25. Papakostas GI, Petersen T, Lebowitz BD, et al.The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005;8(4):523-528.
26. Coppen A, Bolander-Gouaille C. Treatment of depression: Time to consider folic acid and vitamin B12. J Psychopharmacol. 2005;19(1):59-65.
27. Wollack JB, Makori B, Ahlawat S, et al.Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model. J Neurochem. 2008;104(6):1494-503.
28. Serot JM, Christmann D, Dubost T, Bene MC, Faure GC. CSF-folate levels are decreased in late-onset AD patients. J Neural Transm. 2001;108(1):93-99.
29. Bottiglieri T. Homocysteine and folate metabolism in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(7):1103-1112.
30. Bakker DJ, de Jong-van den Berg LT, Fokkema MR. Controlled study on folate status following folic acid supplementation and discontinuation in women of childbearing age. Ann Clin Biochem. 2009;46(pt 3):231-234.
31. Amilburu A, Idoate I, Ponz F, Larralde J. Inhibition of intestinal absorption of 5- methyltetrahydrofolate by fluoxetine. J Physiol Biochem. 2001;57(2):71-80.
32. Wulffele MG, Kooy A, Lehert P, et al.Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: A randomized placebo-controlled trial. J Intern Med. 2003;254(5):455-463.
33. Sobczynska-Malefora A, Harrington DJ, Lomer MC, et al.Erythrocyte folate and 5-methyltetrahydrofolate levels decline during 6 months of oral anticoagulation with warfarin. Blood Coagul Fibrinolysis. 2009;20(4):297-302.
34. Chanson A, Cardinault N, Rock E, et al.Decreased plasma folate concentration in young and elderly healthy subjects after a short-term supplementation with isotretinoin. J Eur Acad Dermatol Venereol. 2008;22(1):94-100.
35. Kelly CB, McDonnell AP, Johnston TG, et al.The MTHFR C677T polymorphism is associated with depressive episodes in patients from Northern Ireland. J Psychopharmacol. 2004;18(4):567-571.
36. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A HuGE review. Am J Epidemiol. 2007;165(1):1-13.
37. Kadouri A, Corruble E, Falissard B. The improved Clinical Global Impression Scale (iCGI): Development and validation in depression. BMC Psychiatry. 2007;7:7.
38. Busner J, Targum SD. The Clinical Global Impressions Scale: Applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28-37.
39. Delgado P, Moreno F. Antidepressants and the brain. Int Clin Psychophramacol. 1999;14(Suppl 1):S9-16.
40. Bottiglieri T, Lanundy M, Crellin R, et al.Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000;69(2):228-232.
41. Surtees R, Heales S, Bowron A. Association of cerebrospinal fluid deficiency of 5- methyltetrahydrofolate, but not Sadenosylmethionine, with reduced concentrations of the acid metabolites of 5-hydroxytryptamine and dopamine. Clin Sci (Lond). 1994;86(6):697-702.
42. Gaynes BN, Davis L, Rush AJ, et al.The aims and design of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatry Res. 2006;141(2):193-200. Epub 2006 Feb 2.